Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Cancer immunotherapy has recently emerged as a forefront strategy to fight cancer. Key players in antitumor responses are CD8+ cytolytic T lymphocytes (CTLs) that can detect tumor cells that carry antigens, in other words, small peptides bound to surface major histocompatibility complex (MHC) class I molecules. The success and safety of cancer immunotherapy strategies depends on the nature of the antigens recognized by the targeted T cells, their strict tumor specificity, and whether tumors and antigen-presenting cells can efficiently process the peptide. We review here the nature of the tumor antigens and their potential for the development of immunotherapeutic strategies. We also discuss the importance of proteasome in the production of these peptides in the context of immunotherapy and therapeutic cancer vaccines.

Original publication

DOI

10.1016/j.trecan.2017.07.007

Type

Journal article

Journal

Trends Cancer

Volume

3

Pages

726 - 741

Keywords

MHC class I, cytolytic T lymphocytes, immunotherapy, proteasome, tumor antigens, Animals, Antigen Presentation, Antigens, Neoplasm, CD8-Positive T-Lymphocytes, HLA Antigens, Humans, Immunotherapy, Neoplasms, Proteasome Endopeptidase Complex, T-Lymphocyte Subsets